Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.46 |
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 0.37 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18954563 | 0.98 | CYP19A1 (0.49) | CYP19A1EPHX1NAAACHRM3HTT | |
| SCHEMBL3345151 | 0.98 | CYP19A1 (0.47) | CYP19A1EPHX1NAAACHRM3HTT | |
| SCHEMBL4673661 | 0.96 | CYP19A1 (0.50) | CYP19A1EPHX1NAAACHRM3HTT | |
| Hydrochloric Acid SCHEMBL18954396 | 0.96 | CYP19A1 (0.42) | CYP19A1EPHX1NAAACHRM3HTT | |
| SCHEMBL21103611 | 0.94 | CYP19A1 (0.44) | CYP19A1EPHX1NAAACHRM3HTT | |
| Hydrochloric Acid SCHEMBL25251995 | 0.82 | MAPT (0.46) | CYP19A1EPHX1CHRM3HTTNPC1 | |
| Hydrochloric Acid SCHEMBL22301617 | 0.82 | KAT2B (0.36) | CYP19A1CHRM3SMN1; SMN2ATM | |
| SCHEMBL21796112 | 0.82 | CYP19A1 (0.35) | CYP19A1NAAACHRM3HTTSMN1; SMN2 | |
| SCHEMBL16575246 | 0.82 | CYP19A1 (0.45) | CYP19A1EPHX1NAAACHRM3HTT | |
| SCHEMBL1682649 | 0.80 | CYP19A1 (0.50) | CYP19A1EPHX1NAAACHRM3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386512-B1 | ANTIVIRAL PHOSPHODIAMIDE PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3503895-B1 | ANTIVIRAL PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME (US) | 2021-09-15 | — | — | EP | disclosed |
| US-10736908-B2 | Antiviral aryl-amide phosphodiamide compounds | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10449208-B2 | Antiviral prodrugs of tenofovir | MERCK SHARP & DOHME CORP. (US) | 2019-10-22 | — | — | US | disclosed |
| EP-3532069-A1 | ANTIVIRAL ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20190262365-A1 | ANTIVIRAL ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190183912-A1 | ANTIVIRAL PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| EP-3386512-A1 | ANTIVIRAL PHOSPHODIAMIDE PRODRUGS OF TENOFOVIR | Merck Sharp & Dohme Corp. (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018080903-A1 | ANTIVIRAL ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2017100108-A1 | ANTIVIRAL PHOSPHODIAMIDE PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME CORP. (US) | 2017-06-15 | — | — | WO | disclosed |
| EP-2285797-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | Chroma Therapeutics Ltd. (GB) | 2011-02-23 | — | — | EP | disclosed |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MACROPHAGE PHARMA LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | c/o Chroma Therapeutics Ltd. (GB) | 2010-12-16 | — | — | US | disclosed |
| EP-2252328-A2 | INTRACELLULAR ENZYME AND RECEPTOR MODULATION | Chroma Therapeutics Ltd. (GB) | 2010-11-24 | — | — | EP | disclosed |
| EP-2245012-A1 | INHIBITORS OF P38 MAP KINASE | Chroma Therapeutics Limited (GB) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010097586-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009141575-A1 | INHIBITORS OF PLK | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009130475-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD., (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009106848-A2 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106844-A1 | INHIBITORS OF P38 MAP KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736908-B2 | Antiviral aryl-amide phosphodiamide compounds | PNP, TYMP, DUT | CYP19A1 1127/4885CHRM3 4696/4885CA2 4584/4885 |
| US-20190183912-A1 | ANTIVIRAL PRODRUGS OF TENOFOVIR | PNP, TYMP, HPRT1 | CYP19A1 1189/4885CHRM3 4651/4885CA2 1327/4885 |
| US-10449208-B2 | Antiviral prodrugs of tenofovir | PNP, TYMP, HPRT1 | CYP19A1 1189/4885CHRM3 4651/4885CA2 1327/4885 |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MAPK3, MAPK1, MAPKAPK3 | CYP19A1 1233/4885CHRM3 620/4885CA2 582/4885 |
| US-20190262365-A1 | ANTIVIRAL ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS | PNP, TYMP, DUT | CYP19A1 1127/4885CHRM3 4696/4885CA2 4584/4885 |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | CYP19A1 612/4885CHRM3 412/4885CA2 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.